Metabolic / Weight Loss · 5mg × 10 vials
In plain terms: Semaglutide is a weight-loss compound - injectable, long-acting and well studied.
Semaglutide is a once-weekly injectable GLP-1 receptor agonist. It's a long-acting analog of the natural gut hormone GLP-1 (glucagon-like peptide-1), engineered with an albumin-binding fatty acid side chain that drags the half-life out to about 7 days so it can be dosed weekly instead of daily like the older GLP-1s (liraglutide). One receptor, one job: it activates GLP-1R in the pancreas (boosting glucose-dependent insulin release, suppressing glucagon), the gut (slowing gastric emptying so food stays put longer), and the brain (arcuate nucleus + brainstem appetite centers, which is where the "food noise goes quiet" effect comes from). The result is reduced caloric intake, delayed gastric emptying, and improved glycemic control. Unlike tirzepatide (dual GLP-1/GIP) and retatrutide (triple GLP-1/GIP/glucagon), semaglutide hits only GLP-1, which is why it has the longest safety record, the gentlest receptor profile, and the most predictable response for first-time GLP-1 users, but also produces less weight loss than the dual and triple agonists. Brand names: Ozempic (T2D, max 2 mg/wk), Wegovy (obesity, max 2.4 mg/wk), Rybelsus (oral tablet, 14 mg/day max).
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
At 10 mg vial + 2 ml BAC = 5 mg/ml, 0.25 mg = 5 IU on a U-100 syringe. Sema is the gentlest on-ramp of any GLP-1, which is why it's the right pick for first-timers who are nervous about nausea or have GI sensitivity. Some compounded protocols and community microdosers start even lower at 0.125 mg/wk for the first 2 weeks before standard 0.25 mg, especially for users under 150 lb or with prior bad GLP-1 experiences. Inject any day of the week, same day going forward.
STEP-1 data shows weight loss curve is roughly linear through this band, with average loss hitting 9-12% by week 28 at 1.0-1.7 mg. SUSTAIN-7 found 1.0 mg sema dropped A1C 1.8% and weight 6.5 kg over 40 weeks in T2D patients, beating dulaglutide head-to-head. Sulfur burps and constipation peak in this band more than at 0.5 mg, often requires fiber + magnesium routine.
STEP-1 at 2.4 mg averaged 14.9% body weight loss at 68 weeks. STEP-5 confirmed sustained loss at 15.2% over 104 weeks (2 years), meaning the effect doesn't taper if you stay on. STEP-UP at 7.2 mg pushed mean loss closer to 20% but with proportionally higher AE rates. Maintenance taper to 1.0-1.7 mg/wk is typical after hitting target weight, because STEP-4 showed dropping the drug entirely caused two-thirds of lost weight to return within 12 months. Most advanced users running sema have either hit ceiling and want to switch to tirz/reta for more potency, or are intentionally staying on sema for longevity/CV-protection reasons (SELECT trial).
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
pivotal obesity efficacy, 1961 pts, 68 weeks, 14.9% mean weight loss at 2.4 mg
Read study ↗PubMed / LancetDavies et al., Lancet 2021 - STEP-2 trial00213-0/abstract) - T2D + obesity, semaglutide 2.4 mg outperformed both 1.0 mg and placebo for weight management
Read study ↗PubMed / Nature MedicineGarvey et al., Nature Med 2022 - STEP-5 trial 2-year datasustained 15.2% loss at 104 weeks, no tapering of effect
Read study ↗PubMed / JAMARubino et al., JAMA 2022 - STEP-8 head-to-head vs liraglutidesema 15.8% vs lira 6.4% at 68 weeks, sema 6.3× more likely to hit 10% loss
Read study ↗PubMed / NEJMWadden et al., JAMA 2021 - STEP-3 intensive behavioral therapy16.0% weight loss with sema + IBT vs 5.7% IBT alone
Read study ↗PubMed / JAMARubino et al., JAMA 2021 - STEP-4 maintenance trialwithdrawal of sema after 20 wk run-in led to weight regain; continued use maintained loss
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Nausea: most-reported sensation, peaks weeks 4-12, manageable with low-fat meals 48 hr post-injection, ginger tea, and Sunday-night dosing so peak nausea hits during weekend rest
- Divergence: RCT reports 44%, community surveys (r/Semaglutide, r/Ozempic, r/Wegovy) report closer to 60-70% have at least mild nausea during titration, though severe nausea matches the trial 24% figure
Sulfur burps: the signature sema complaint - rotten egg/sulfur-smelling burps from slowed gastric emptying causing food to ferment longer. Up to 20-30% report this on community surveys. Trial reports lump this under "eructation" or "dyspepsia" at much lower rates.
- Divergence: Community calls sulfur burps "the sema problem" while RCT data barely flags it; tirz and reta users report this much less, sema is uniquely bad for it
Fatigue: more often reported in community than literature flags it, especially weeks 1-4 of each new dose step. r/Wegovy threads consistently describe "the sema slumps"
- Divergence: RCT says 11%, community surveys report closer to 30-40% during titration
Route: SubQ
Injection site: abdomen, outer thigh, or back of upper arm, rotate sites weekly
Storage: refrigerated 36-46°F, 28-56 days post-reconstitution (semaglutide is the most stable GLP-1 once mixed, longer shelf life than tirz/reta)
Notes: Same weekday each week, time of day doesn't matter (long half-life smooths out timing). Many community users dose Sunday night to put peak nausea on a weekend when work demands are lower. Allow vials to reach room temp before injecting once reconstituted. Don't shake (swirl gently). Use a fresh U-100 insulin syringe per draw. Rybelsus (oral) has 0.4-1% bioavailability and must be taken with no more than 4 oz of plain water on an empty stomach, then wait 30 min before eating or drinking anything else.